首页> 外文OA文献 >Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial

【2h】

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial

机译：一线推荐ACT（QUINACT）失败后，采用相同的基于青蒿素的联合治疗（ACT）与另一种ACT和奎宁加克林霉素进行再治疗的疗效和安全性：双中心，开放标签，第3期，随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mavoko Hypolite Muhindo; Nabasumba Carolyn; da Luz Raquel Inocêncio; Tinto Halidou; DAlessandro Umberto; Kambugu Andrew; Baraka Vito; Rosanas-Urgell Anna; Lutumba Pascal; Van geertruyden Jean-Pierre;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial [J] . Hypolite Muhindo Mavoko, Carolyn Nabasumba, Raquel Inocêncio da Luz, The Lancet Global Health . 2017,第1期

机译：与替代行为（ACT）相比，重新治疗的疗效和安全性与替代行为和奎宁加克林霉素在第一线推荐法案失败后（Quinact）：双门，开放标签，第3阶段，随机化受控试验
2. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial [J] . West Howard, McCleod Michael, Hussein Maen, The lancet oncology . 2019,第7期

机译：atezolizumab与Carboplatin Plus Nab-Paclitaxel化疗相结合，与单独的化学疗法相比，作为转移性非鳞状非小细胞肺癌的一线治疗（Impower130）：多期，随机，开放标签，第3阶段试验
3. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2eu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial [J] . Welt A., Marschner N., Lerchenmueller C., Breast cancer research and treatment. . 2016,第1期

机译：卡培他滨和贝伐单抗联合或不联合长春瑞滨用于HER2 /中性阴性转移性或局部晚期乳腺癌的一线治疗：随机，开放标签优越性3期CARIN试验的最终疗效和安全性数据
4. A Phase 3 Open-label Randomized Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia Acute Lung Injury or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial [O] . Keisha Smith, Amy Pace, Stephan Ortiz, -1

机译：与COVID-19严重肺炎急性肺损伤或急性呼吸窘迫综合征患者的最佳支持治疗相比评估静脉内施用Ravulizumab与最佳支持治疗的疗效和安全性的3期开放标签随机对照研究：随机对照试验的研究方案
5. Effi cacy and safety of re-treatment with the sameudartemisinin-based combination treatment (ACT) comparedudwith an alternative ACT and quinine plus clindamycin afterudfailure of fi rst-line recommended ACT (QUINACT): a bicentre,udopen-label, phase 3, randomised controlled trial [O] . Muhindo Mavoko Hypolite, Nabasumba Carolyn, Inocêncio da Luz Raquel, 2017

机译：相同的治疗效果和安全性基于青蒿素的联合治疗（ACT）的比较 ud ud后使用其他ACT和奎宁加克林霉素治疗一线推荐ACT（QUINACT）失败：双中心， ud开放标签，第3期，随机对照试验

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial

著录项

引文网络

相似文献

相关主题

期刊订阅